imatinib mesylate has been researched along with Adverse Drug Event in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (25.53) | 29.6817 |
| 2010's | 23 (48.94) | 24.3611 |
| 2020's | 12 (25.53) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Afacan Öztürk, HB; Albayrak, M; Maral, S; Reis Aras, M; Sağlam, B; Tığlıoğlu, M; Tığlıoğlu, P; Yılmaz, F | 1 |
| Cherix, S; Digklia, A; Dolcan, A; Koulouris, P; Matter, M; Omoumi, P; Papadopoulos, S; Royer-Chardon, C; Tsoumakidou, G | 1 |
| Kiat-Amnuay, S; Myers, AL; Wang, BY | 1 |
| Dirkson, A; Gelderblom, H; Kraaij, W; van Oortmerssen, G; Verberne, S | 1 |
| Ito, Y; Kondo, M; Koseki, T; Tanaka, J; Yamada, S | 1 |
| Adattini, JA; Gross, AS; McLachlan, AJ; Wong Doo, N | 1 |
| Chen, F; Shi, Z; Wang, J; Wu, F; Xie, R; Yao, W | 1 |
| Despas, F; Lapeyre-Mestre, M; Pajiep, M | 1 |
| Chaturvedi, A; Thapa, M | 1 |
| Bernard, PS; Kim, K; McMillin, GA; Schmidt, RL; Tantravahi, S; Walker, BS | 1 |
| Beijnen, JH; Groenland, SL; Huitema, ADR; IJzerman, NS; Kerst, M; Koenen, AM; Rosing, H; Steeghs, N; van der Graaf, WTA | 1 |
| Ciaffi, J; Ciccia, F; Cipriani, P; Giacomelli, R; Liakouli, V; Meliconi, R; Ruscitti, P; Ursini, F | 1 |
| Ar, MC; Aydın, Y; Başlar, Z; Bayraktar, EA; Bektaş, F; Elverdi, T; Eşkazan, AE; Keskin, D; Öngören, Ş; Özgür Yurttaş, N; Özmen, D; Öztaş, M; Sadri, S; Salihoğlu, A; Soysal, T | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Aparicio, T; Arsène, D; Bertucci, F; Bisot-Locard, S; Blay, JY; Bouché, O; Bourges, O; Cesne, AL; Chabaud, S; Chaigneau, L; Collard, O; Duffaud, F; Isambert, N; Italiano, A; Lecomte, T; Manfredi, S; Priou, F; Remy, S; Rios, M; Sambuc, R | 1 |
| Chen, L; Chen, M; He, Z; Li, Q; Qian, Y; Sun, L; Sun, X; Wang, L; Wang, Y; Xu, H; Xu, J; Xu, K; Xu, Z; Yang, L; Zhang, D; Zhang, Q | 1 |
| Cai, W; Chen, H; Hou, Y; Liu, J; Ma, G; Zhou, Y | 1 |
| Alimena, G; Breccia, M | 1 |
| Besson, N; Brümmendorf, TH; Cortes, JE; Durrant, S; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Martinelli, G; Porkka, K; Turnbull, K | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Hochhaus, A | 1 |
| Albright, F; Bauer, H; Brixner, DI; Chen, L; Deininger, MW; Kuo, KL; Raimundo, K; Shami, PJ; Stenehjem, DD | 1 |
| Ayrton, J; Dezube, BJ; Kwak, E; Lyons, J; Mahadevan, D; Shapiro, GI; Yule, M | 1 |
| Wissing, MD | 1 |
| Oshima, Y; Tojo, A; Yuji, K | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Andorsky, D; Assouline, S; Baccarani, M; Chuah, C; Clackson, T; Clark, RE; Cortes, JE; Deininger, MW; Etienne, G; Guerci-Bresler, A; Guilhot, F; Haluska, FG; Hochhaus, A; Hughes, T; Kantarjian, HM; le Coutre, P; Lipton, JH; Lustgarten, S; Nicolini, FE; Oehler, V; Rivera, VM; Rosti, G; Shah, NP; Simpson, D; Stenke, L; Talpaz, M | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Avanzini, P; Binotto, G; Bocchia, M; Bonifacio, M; Breccia, M; Bucelli, C; Calistri, E; Castagnetti, F; Cattaneo, D; Cavazzini, F; Cedrone, M; Celesti, F; Cortelezzi, A; Cortesi, L; Crugnola, M; D'Addosio, AM; Falzetti, F; Fava, C; Ferrero, D; Galimberti, S; Giglio, G; Gozzini, A; Gugliotta, G; Isidori, A; Iurlo, A; Latagliata, R; Luciano, L; Mannucci, PM; Mansueto, G; Mauro, E; Montefusco, E; Nobili, A; Orlandi, EM; Pregno, P; Rege-Cambrin, G; Rossi, AR; Rosti, G; Russo, S; Saglio, G; Scaffidi, L; Sica, S; Sorà, F; Spadea, A; Stagno, F; Storti, S; Tettamanti, M; Tiribelli, M; Vigneri, P | 1 |
| Bondon-Guitton, E; Bourrel, R; Chebane, L; Despas, F; Lapeyre-Mestre, M; Montastruc, JL; Récoché, I; Rousseau, V | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Foedermayr, M; Krieger, O; Lutz, D; Zach, O; Zellhofer, B | 1 |
| Bailey, SM; Bertulli, R; Blay, JY; Borghaei, H; Casali, PG; Cassier, P; Cheung, W; Davey, M; Debiec-Rychter, M; Demetri, GD; Fumagalli, E; Morgan, JA; Pink, D; Ray-Coquard, I; Reichardt, A; Reichardt, P; Veronese, ML; von Mehren, M | 1 |
| Apperley, J | 1 |
| Balzer-Haas, NS; DeConti, RC; Flaherty, LE; Heinrich, MC; Merl, SA; Moon, J; Samlowski, WE; Sondak, VK; Thompson, JA; Tuthill, RJ; Witter, MT | 1 |
| Dobashi, N; Ezaki, K; Higashihara, M; Hiraoka, A; Kanakura, Y; Kiyoi, H; Miyazaki, Y; Motoji, T; Nagai, T; Nakao, S; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Okada, M; Shinagawa, K; Takeuchi, J; Taniguchi, S; Tsukamoto, N; Usui, N | 1 |
| Kim, TD; le Coutre, P | 1 |
| Baruchel, A; Bernard, F; Berthou, C; Bertrand, Y; Bordigoni, P; Cayuela, JM; Couillault, G; Edan, C; Galambrun, C; Guilhot, F; Guilhot, J; Leblanc, T; Lutz, P; Mazingue, F; Méchinaud, F; Millot, F; Petit, A; Reguerre, Y; Vérité, C; Yacouben, K | 1 |
| Boku, N; Doi, T; Hirota, S; Kakeji, Y; Kanda, T; Katai, H; Kikuchi, S; Kobayashi, O; Komatsu, Y; Koseki, M; Miyachi, K; Nishida, T; Ogoshi, K; Ohtsu, A; Sawaki, A; Sugiyama, T; Toh, Y; Wada, N; Yamamoto, M | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kondo, K; Matsuno, K; Mori, A; Musashi, M; Onozawa, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Countouriotis, AM; Druker, BJ; Ezzeddine, R; Facon, T; Goldberg, SL; Hochhaus, A; Hughes, TP; Kantarjian, HM; Lipton, JH; Muller, MC; Niederwieser, D; Shah, NP; Silver, RT; Stone, RM | 1 |
| Apanovitch, AM; Coutre, S; Dombret, H; Gollerkeri, A; Guilhot, F; Hochhaus, A; Larson, RA; Martinelli, G; Ottmann, O; Radich, J; Rege-Cambrin, G; Simonsson, B | 1 |
| Al Bahar, S; Pandita, R; Prakash, A; Ramamoorthy, SK; Ramaswamy, NV | 1 |
| Cortes, J; Druker, B; Fischer, T; Gambacorti, C; Gambacorti-Passerini, C; Goldman, J; Guilhot, F; Hochhaus, A; Kantarjian, HM; Krahnke, T; Mone, M; Niederwieser, DW; O'Brien, SG; Reiffers, JJ; Sawyers, C; Schiffer, CA; Stone, RM; Talpaz, M | 1 |
| de Jong, FA; Gietema, JA; Perik, PJ; Rikhof, B; van der Graaf, WT; Verweij, J | 1 |
| Wassmann, B | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
8 review(s) available for imatinib mesylate and Adverse Drug Event
| Article | Year |
|---|---|
Drug-drug interactions of protein kinase inhibitors in chronic myeloid leukaemia patients: A study using the French health insurance database.
Topics: Antineoplastic Agents; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Insurance, Health; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Quality of Life; Scleroderma, Systemic; Skin; Treatment Outcome | 2020 |
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Chemotherapy- and irradiation-induced bone loss in adults with solid tumors.
Topics: Adult; Antineoplastic Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Methotrexate; Neoplasms; Radioisotopes; Radiotherapy; Taxoids | 2015 |
Issues of imatinib and pregnancy outcome.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Animal; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Risk Factors; Teratogens | 2009 |
The expanding role of nilotinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
14 trial(s) available for imatinib mesylate and Adverse Drug Event
| Article | Year |
|---|---|
Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Polymorphism, Single Nucleotide | 2018 |
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Withholding Treatment; Young Adult | 2014 |
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Topics: Adult; Aged; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoindoles; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Urinary Bladder Neoplasms | 2015 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pyridazines; Treatment Outcome | 2016 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).
Topics: Aged; Aged, 80 and over; Benzamides; Carcinoma, Merkel Cell; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Survival Analysis | 2010 |
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Topics: Adolescent; Adult; Aged; Benzamides; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; France; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis | 2011 |
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Postoperative Period; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2013 |
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Thiazoles; Treatment Failure | 2007 |
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Time Factors | 2007 |
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2008 |
25 other study(ies) available for imatinib mesylate and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Drug-Related Side Effects and Adverse Reactions; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Vitreous Hemorrhage | 2022 |
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Topics: Drug-Related Side Effects and Adverse Reactions; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Lymphadenopathy; Protein Kinase Inhibitors | 2022 |
Effect of imatinib on oral wound healing after extraction: A rare case report.
Topics: Alveolar Ridge Augmentation; Dentists; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Male; Middle Aged; Professional Role; Tooth Extraction; Tooth Socket; Wound Healing | 2022 |
Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Neoplasms; Pharmacovigilance; Quality of Life | 2022 |
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Japan; Lapatinib; Pharmacovigilance; Tamoxifen | 2022 |
Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.
Topics: Australia; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study.
Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Hospitals; Humans; Imatinib Mesylate; Protein Kinase Inhibitors | 2022 |
Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nail Diseases; Pigmentation Disorders | 2020 |
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cost-Benefit Analysis; Cytogenetic Analysis; Drug Monitoring; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Pharmacogenomic Testing; Quality-Adjusted Life Years; Survival Analysis | 2019 |
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
Topics: Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Netherlands; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies | 2020 |
Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2021 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
Topics: Adult; Aged; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Edema; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Treatment Outcome | 2018 |
Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Genotype; Hepatocyte Nuclear Factor 4; Humans; Imatinib Mesylate; Male; Middle Aged; Pharmacogenetics; Plasma; Polymorphism, Genetic; Young Adult | 2019 |
Optimizing tolerability of TKI therapy in CML.
Topics: Aniline Compounds; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines | 2014 |
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.
Topics: Adult; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis | 2014 |
"Imatinib-induced gastric antral vascular ectasia" in a reporting system of the Japanese Adverse Drug Event Report database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastric Antral Vascular Ectasia; Humans; Imatinib Mesylate; Japan; Leukemia; Male; Middle Aged | 2016 |
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Polypharmacy; Treatment Outcome | 2016 |
Drug-drug interactions with imatinib: An observational study.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Agents; Child; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; France; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Retrospective Studies; Substance-Related Disorders; Young Adult | 2016 |
OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Octamer Transcription Factor-1; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Young Adult | 2008 |
Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Proliferation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Leukemic; Genes, abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Pyrimidines | 2006 |
Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Jaundice, Obstructive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Piperazines; Pyrimidines | 2007 |
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
Topics: Administration, Oral; Adult; Aged; Benzamides; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Peptide Fragments; Piperazines; Probability; Prospective Studies; Pyrimidines; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Troponin T | 2008 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |